General Information
Lilly COVID PYAB
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 in Participants with Mild to Moderate COVID-19 Illness
| Protocol | J2W-MC-PYAB |
|---|---|
| Identifier | PO 4900744197 |
| UID | 8866a714-0dc3-4019-b04b-d37c793911b0 |
| Status | Done - Archived |
| Phase | 2 |
| Category | COVID-19 / Adult |
| Launch Year | 2020 |
| NCT Number | - |
| Created | 2020-07-20 13:24 |
| Last Updated | 2020-07-20 13:24 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2020-09-11 | No |
| Enrollment Open | 2020-08-06 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2020-07-31 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2021-08-03 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | - | No | |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Eli Lilly and Company |
|---|---|
| Division | Lilly |
| Team | Lilly |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
